Bio-Techne and Oxford Nanopore Technologies Strengthen Partnership
In an exciting development for the genetic testing landscape, Bio-Techne Corporation (NASDAQ: TECH) has made significant strides by enhancing its collaboration with Oxford Nanopore Technologies. This expanded agreement positions Bio-Techne to broaden its portfolio of genetic products, capitalizing on Oxford Nanopore's cutting-edge platforms. The renewed collaboration extends through 2032, helping to meet the growing demands of laboratories worldwide.
New Development Framework Established
This agreement lays out a strategic framework that allows Bio-Techne to define and propose future product portfolios, further solidifying its position as a leader in the diagnostics industry. Building on the positive reception of the AmplideX® Nanopore Carrier Plus Kit, which was launched in 2025, the partnership aims to streamline the development and commercialization of new targeted enrichment sequencing kits. These kits are vital in screening and diagnosing heritable genetic disorders, transforming the way laboratories approach genetic health.
Commitment to Genetic Testing Innovations
The leadership teams of both companies express a shared vision for advancing genetic testing solutions. Matt McManus, President of Bio-Techne’s Diagnostics and Spatial Biology Segment, emphasizes the importance of this agreement in simplifying workflows and enhancing the insights available to laboratories globally. He states, "Our deeper collaboration with Oxford Nanopore is set to foster innovation in diagnostics, establishing a robust foundation for future developments in genetic testing products."
Transforming Testing Accessibility
Rosemary Dokos, Chief Product and Marketing Officer of Oxford Nanopore Technologies, shared her enthusiasm about the collaboration, noting how combining Bio-Techne’s expertise in diagnostics with their advanced molecular sensing technologies will lead to faster, simpler, and more accessible testing solutions. This synergy is pivotal in making genetic testing available to a broader range of laboratories, potentially saving lives through early diagnosis and treatment.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a prominent global life sciences company specializing in providing innovative tools and bioactive reagents for research and clinical diagnostics. The vast range of products offered by Bio-Techne aids in scientific exploration, seeking to uncover biological processes and gain a deeper understanding of diseases. This expansive portfolio also supports drug discovery initiatives, ensuring accurate clinical tests and diagnoses. The company reported impressive sales of over $1.2 billion in its latest fiscal year and employs around 3,100 staff members across the globe.
About Oxford Nanopore Technologies
Oxford Nanopore Technologies stands at the forefront of innovation, with a vision of enabling anyone to analyze anything from anywhere in the world. Their nanopore-based sensing technology is revolutionary, currently utilized for comprehensive, rapid, and affordable DNA and RNA analysis. This platform aims to expand its applications to proteins and metabolites, with its technology being employed in over 125 countries. Through this extensive reach, Oxford Nanopore is contributing to the understanding of the biology of various organisms and the causes of numerous diseases.
Frequently Asked Questions
What is the significance of the partnership between Bio-Techne and Oxford Nanopore?
This partnership enhances Bio-Techne's ability to develop a variety of genetic products using Oxford Nanopore's technologies, which ultimately leads to better diagnostic tools.
How will the new frameworks benefit laboratories?
The frameworks enable quicker development of new testing kits, allowing laboratories to conduct screenings and diagnoses of genetic disorders more efficiently.
What are some products resulting from this collaboration?
One notable product is the AmplideX® Nanopore Carrier Plus Kit, which enhances genetic testing capabilities and supports the detection of heritable disorders.
How has Bio-Techne performed financially?
Bio-Techne generated over $1.2 billion in net sales in fiscal 2025, underscoring its strong market presence and demand for its products.
What types of diseases are being addressed through this collaboration?
The collaboration aims to address heritable genetic disorders, enhancing the options available for early detection and treatment.
